Journal of Gynecologic Oncology最新文献

{"title":"Prevalence of high-risk human papillomavirus genotypes among women in Uzbekistan, 2021-2023.","authors":"Iroda Pulatovna Sharipova, Erkin Isakovich Musabaev, Shakhlo Sobirovna Sadirova, Dildora Tolibjonovna Suyarkulova, Shavkat Ekrinovich Tashev, Shakhnoza Khayrullaevna Akhmedova, Nozimakhon Rakhmatullaxodjaevna Turabova, Saidkhon Makhmudkhonovich Sharapov, Rano Ibrahimovna Kasimova, Ravshan Abdullaevich Rakhimov, Guljakhon Toyirovna Yuldashova, Kyutaeg Lee, Gayoung Chun, Hyunwon Kim","doi":"10.3802/jgo.2025.36.e7","DOIUrl":"10.3802/jgo.2025.36.e7","url":null,"abstract":"<p><strong>Objective: </strong>Cervical cancer remains a significant global health concern. Extensive research has established a critical link between human papillomavirus (HPV) infection and the development of cervical cancer. As a result, high-risk HPV (Hr-HPV) testing has emerged as a promising screening method. This study aimed to retrospectively analyze the prevalence of Hr-HPV genotypes among women in three regions of Uzbekistan.</p><p><strong>Methods: </strong>Between 2021 and 2023, the Research Institute of Virology of Uzbekistan and the Korea Foundation for International Healthcare conducted a comprehensive population-based study in Tashkent, Andijan, and Samarkand. The study targeted 43,921 women aged 20 and above, utilizing real-time polymerase chain reaction to investigate the prevalence of 12 Hr-HPV genotypes. The analysis included an examination of the distribution of these genotypes based on age, region, and various demographic factors.</p><p><strong>Results: </strong>The overall prevalence of Hr-HPV among women aged 20 and above in Uzbekistan was 7.4%. Regional variations were observed and Hr-HPV prevalence was higher in individuals in their 20s than in other age groups in all 3 regions (p<0.001). The proportion of HPV 16 and 18 was 32.5% and 6.4% in the single infections, 41.9% and 14.7% in the double infections, and 59.3% and 20.0% in the multiple infections. There were also significant differences in prevalence across demographic factors, such as marital status, parity, current smoking, and contraceptive method (p<0.005).</p><p><strong>Conclusion: </strong>The findings emphasize the importance of early screening and educational initiatives, particularly targeting young and co-infected women. This foundational data aims to improve women's health strategies in Uzbekistan.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":"36 1","pages":"e7"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical practice guidelines for ovarian cancer: an update to the Korean Society of Gynecologic Oncology guidelines.","authors":"Banghyun Lee, Suk-Joon Chang, Byung Su Kwon, Joo-Hyuk Son, Myong Cheol Lim, Yun Hwan Kim, Shin-Wha Lee, Chel Hun Choi, Kyung Jin Eoh, Jung-Yun Lee, Yoo-Young Lee, Dong Hoon Suh, Yong Beom Kim","doi":"10.3802/jgo.2025.36.e69","DOIUrl":"10.3802/jgo.2025.36.e69","url":null,"abstract":"<p><p>We updated the Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of ovarian cancer as version 5.1. The ovarian cancer guideline team of the KSGO published announced the fifth version (version 5.0) of its clinical practice guidelines for the management of ovarian cancer in December 2023. In version 5.0, the selection of the key questions and the systematic reviews were based on the data available up to December 2022. Therefore, we updated the guidelines version 5.0 with newly accumulated clinical data and added 5 new key questions reflecting the latest insights in the field of ovarian cancer between 2023 and 2024. For each question, recommendation was provided together with corresponding level of evidence and grade of recommendation, all established through expert consensus.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":"36 1","pages":"e69"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early prediction and risk stratification of ovarian cancer based on clinical data using machine learning approaches.","authors":"Ting Gui, Dongyan Cao, Jiaxin Yang, Zhenhao Wei, Jiatong Xie, Wei Wang, Yang Xiang, Peng Peng","doi":"10.3802/jgo.2025.36.e53","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e53","url":null,"abstract":"<p><strong>Objective: </strong>Our study was aimed to construct a predictive model to advance ovarian cancer diagnosis by machine learning.</p><p><strong>Methods: </strong>A retrospective analysis of patients with pelvic/adnexal/ovarian mass was performed. Potential features related to ovarian cancer were obtained as many as possible. The optimal machine learning algorithm was selected among six candidates through 5-fold cross validation. Top 20 features having the most powerful predictive significance were ranked by Shapley Additive Interpretation (Shap) method. Clinical validation was further performed to confirm whether our model could advance diagnosis of ovarian cancer.</p><p><strong>Results: </strong>A total of 9,799 patients were collected. The inclusion criteria included age >18 years old, the first diagnosis being pelvic/adnexal/ovarian mass of undetermined significance, and pathological report indispensable. Four hundred and thirty-eight dimensional features were obtained after filtration. LightGBM showed the best performance with accuracy 88%. Among the top 20 features, 55% belonged to laboratory test report, 35% came from imaging examination report, and 10% were attributed to basic demographics and main symptom. Age, CA125, and risk of ovarian malignancy algorithm were the top three. Our predictive model performed stably in testing and clinical validation datasets, and was found to advance the diagnosis of ovarian cancer about 17 days before clinical pathological examination.</p><p><strong>Conclusion: </strong>LightGBM was the optimal algorithm for our predictive model with accuracy of 88%. Laboratory test and imaging examination played essential roles in diagnosing ovarian cancer. Our model could advance the diagnosis of ovarian cancer before clinical pathological examination.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant hormone therapy and overall survival among low-grade and apparent early-stage endometrial stromal sarcoma patients.","authors":"Kristin L Bixel, Caitlin E Meade, Morgan Brown, Ashley S Felix","doi":"10.3802/jgo.2025.36.e50","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e50","url":null,"abstract":"<p><strong>Objective: </strong>Surgery is the mainstay of treatment for low-grade endometrial stromal sarcoma (LG-ESS). While adjuvant hormone therapy is recommended for patients with advanced/recurrent disease, no consensus regarding its use among early-stage patients exists. We aimed to identify correlates of adjuvant hormone therapy use and associations of adjuvant hormone therapy and overall survival (OS) in stage I LG-ESS patients.</p><p><strong>Methods: </strong>Retrospective cohort study of patients with stage I LG-ESS who underwent hysterectomy from 2004-2019 using data from the National Cancer Database. Categorical data were compared using χ² tests. Kaplan-Meier estimates and log-rank tests were used to compare OS according to adjuvant hormone use. Hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between adjuvant hormone use and OS were estimated using Cox proportional hazards regression.</p><p><strong>Results: </strong>Of 2,386 patients included, 20.2% were treated with adjuvant hormonal therapy. Use of hormone therapy increased over time, with rates approximately doubling from 2004 to 2019 (12.6% to 24.6%). Age, tumor size, lymphovascular space invasion and adjuvant radiation were associated with adjuvant hormone therapy use. There was no association between adjuvant hormone therapy and OS (log-rank p=0.73; HR=1.05; 95% CI 0.76-1.46) for patients with LG-ESS.</p><p><strong>Conclusion: </strong>Use of adjuvant hormone therapy for stage I LG-ESS has increased over time though is not associated with OS in this cohort of patients. Additional evaluation is needed to understand the impact of adjuvant hormone therapy on recurrence rates, progression rates, and quality of life to fully understand its value.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application value of personalized 3D printing vaginal model for the Image-guided adaptive brachytherapy of cervical cancer.","authors":"Zhantuo Cai, Qiuyan Wu, Xinglong Yang, Qinghua Qin, Yiqian Zhang, Zhouyu Li, Mingyi Li","doi":"10.3802/jgo.2025.36.e48","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e48","url":null,"abstract":"<p><strong>Objective: </strong>To explore the application value of using 3-dimensional (3D) printing (3DP) technology to create individualized vaginal molds for brachytherapy (BT) in high-dose-rate 3D cervical cancer through reverse engineering of needle placement.</p><p><strong>Methods: </strong>Prospectively, 11 patients with cervical cancer were treated with 3DP-intracavitary/interstitial (IC/IS) BT using 3DP to create individualized vaginal molds. All patients were performed BT after completion of external beam radiotherapy (EBRT). Each patient was treated with BT 5 times, the prescription dose was 600 cGy/F, which was performed once or twice a week, 2 of them were freehand IC/IS BT, and 3 were 3DP-IC/IS BT. The relevant planning parameters (bladder, rectum, sigmoid colon, and small intestine) and target conformity index (CI) for high-risk clinical target volume (HR-CTV) and organs at risk (OARs) were compared between the groups.</p><p><strong>Results: </strong>There were significant advantages in the 3DP-IC/IS BT group compared with the freehand IC/IS BT group: HR-CTV D₉₀ (629.40±19.34 vs. 613.03±15.93 cGy, p=0.002), D₉₅ (580.74±18.31 vs. 567.44±23.94 cGy, p=0.032), bladder D_2cc (431.11±23.27 vs. 458.07±23.27 cGy, p<0.001), bladder D_1cc and bladder D_0.1cc. There was no statistically significant difference (p>0.05) between the 2 groups in rectal D_2cc (352.30±42.42 vs. 361.29±42.42 cGy, p=0.470), sigmoid colon D_2cc (236.73±78.95 vs. 246.50±58.17 cGy, p=0.621), CI (0.79±0.04 vs. 0.79±0.039 p=0.773), HR-CTV V₁₀₀, V₂₀₀, D₉₈, D₁₀₀ and other OARs parameters (p>0.05).</p><p><strong>Conclusion: </strong>Compared with IC/IS BT, 3DP-IC/IS BT has apparent advantages with simple operation and high safety. In addition, individualized mold helps to improve the tumor target area's radiation dose while meeting the dose-limiting requirements for organs at risk and reduces the clinical proficiency requirements for operating physicians.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142895146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shared decision-making in patients with gynecological cancer and healthcare professionals: a cross-sectional observational study in Japan.","authors":"Masakazu Abe, Hironobu Hashimoto, Azusa Soejima, Yumiko Nishimura, Ami Ike, Michiko Sugawara, Muneaki Shimada","doi":"10.3802/jgo.2025.36.e47","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e47","url":null,"abstract":"<p><strong>Objective: </strong>This cross-sectional study aimed to understand the actual situation of shared decision-making (SDM) and identify the challenges of implementing SDM among Japanese gynecologic cancer patients and healthcare professionals (HCPs).</p><p><strong>Methods: </strong>Adult Japanese women undergoing chemotherapy for endometrial or ovarian/fallopian tube cancer and HCPs who prescribed/administered treatment were enrolled. Data were collected via a web-based questionnaire. Primary endpoints were the actual and desired status of SDM for patients by preferred role (active, collaborative, passive), and important aspects in drug selection for patients and HCPs. SDM treatment preferences were determined using the Control Preferences Scale.</p><p><strong>Results: </strong>Respondents comprised 154 patients (77 for endometrial and 77 for ovarian/fallopian tube cancer), 153 physicians, 166 nurses, and 154 pharmacists. Among patients, 53.9% desired an active role in decision-making, and 55.8% participated; 25.3% desired a collaborative role, and 14.3% participated; and 20.8% desired a passive role, and 29.9% participated. Most patients with a collaborative role in decision-making (86.4%) were \"very satisfied\" or \"somewhat satisfied\" with their communication with physicians, compared with 60.4% and 73.9% of respondents with active and passive roles in decision-making, respectively. In daily practice, 23.5%, 47.6%, and 19.5% of physicians, nurses, and pharmacists, respectively, confirmed \"awareness\" of SDM. Regarding treatment expectations, patients ranked \"complete elimination of cancer,\" and HCPs ranked \"live longer\" as the most important.</p><p><strong>Conclusion: </strong>Most patients desire involvement in their treatment decisions. Additionally, treatment expectations differ between patients and HCPs. Increasing SDM awareness, implementing it systematically, and addressing patients' needs for collaborative roles in decision-making is essential.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncological safety of minimally invasive surgery in borderline ovarian tumor and ovarian cancer: a retrospective comparative study.","authors":"Natsuki Osawa, Kenro Chikazawa, Ken Imai, Hiroyoshi Ko, Tomoyuki Kuwata, Ryo Konno","doi":"10.3802/jgo.2025.36.e46","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e46","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the oncological safety of laparoscopic surgery for patients with benign tumors who underwent laparoscopic surgery at our facility and were subsequently diagnosed with borderline ovarian tumors or ovarian cancer.</p><p><strong>Methods: </strong>We conducted a retrospective review of 45 patients initially diagnosed with benign ovarian tumors who underwent laparoscopic surgery at our institution from January 2009 to April 2024.</p><p><strong>Results: </strong>Postoperative pathological examination identified 32 cases of borderline ovarian tumors and 13 cases of ovarian cancer. Laparoscopic cystectomy was performed in 14 (43.8%) borderline cases and 4 (30.8%) ovarian cancer cases. Out of 14 patients with borderline ovarian tumors who underwent cystectomy, 8 subsequently underwent staging laparotomy, whereas 6 underwent only ovarian tumor cystectomy. In contrast, none of the patients with ovarian cancer completed treatment with only ovarian tumor cystectomy. Recurrent disease was observed in 9.4% of borderline tumor cases, all of which were successfully managed with further surgery. In the ovarian cancer group, recurrence occurred in 31% of patients, with 3 resulting in tumor-related mortality.</p><p><strong>Conclusion: </strong>Laparoscopic surgery for borderline ovarian tumors is suggested to be oncologically safe, with low recurrence rate and no adverse impact on survival. However, for ovarian cancer, particularly in cases with peritoneal dissemination, rapid disease progression remains a concern. While this study suggests that laparoscopic surgery may be a viable option for borderline ovarian tumors, further research is needed to validate these findings, particularly for ovarian cancer.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacokinetics, toxicities, and tissue concentrations of belotecan sprayed by rotational intraperitoneal pressurized aerosol chemotherapy in a pig model.","authors":"Seungmee Lee, Seoyoon Lee, Yoo-Kyung Song, Se-Mi Kim, Yoon Jeong Choi, Seung Jun Lee, San-Hui Lee, Hee Seung Kim","doi":"10.3802/jgo.2025.36.e37","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e37","url":null,"abstract":"<p><strong>Objective: </strong>We evaluated the pharmacokinetics, tissue concentrations, and toxicities of belotecan during rotational intraperitoneal pressurized aerosol chemotherapy (RIPAC) in pigs.</p><p><strong>Methods: </strong>We sprayed belotecan in 10% and 30% of doses for intravenous chemotherapy in six pigs (cohort 1, n=3, 0.50 mg/m²; cohort 2, n=3, 1.5 mg/m²). We evaluated the time-dependent plasma concentrations of belotecan before RIPAC to 120 hours for the pharmacokinetics, tissue concentrations in twelve peritoneal regions, and hepatic and renal functions before RIPAC to 120 hours in the 2 cohorts.</p><p><strong>Results: </strong>Mean values of the peak plasma concentration (C_max), the time to C_max, the time taken for C_max to drop in half, and the area under the curve from time zero to the time of last quantifiable concentration were 905 and 3,700 ng/mL, 1.42 and 1.50 hours, 3.64 and 5.60 hours, and 2,260 and 17,900 pg·hr/mL in cohorts 1 and 2, respectively. Mean values of tissue concentrations were 1.5 to 15.3 times higher in cohort 1 than in cohort 2 despite the similar ratio of tissue to plasma concentration, and tissue concentrations in the two cohorts were higher in the parietal peritoneum than in the visceral peritoneum. However, hepatic and renal functions were not different before RIPAC to 120 hours in the two cohorts.</p><p><strong>Conclusion: </strong>RIPAC using belotecan of 0.5 mg/m² and 1.5 mg/m² may be feasible with fewer hepatic and renal toxicities in pigs. Thus, belotecan of 1.5 mg/m² may be considered as the starting dose for RIPAC in a phase 1 trial.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functions, interactions and prognostic role of <i>POLE</i>: a bioinformatics analysis.","authors":"Jonathan Carvajal-Veloza, Fredy Galindo-Morales, Luz Dary Gutierrez-Castañeda","doi":"10.3802/jgo.2025.36.e45","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e45","url":null,"abstract":"<p><strong>Objective: </strong>To describe <i>POLE</i> characteristics and reported mutations in endometrial cancer (EC) and analyze the impact of these mutations on the structure and function of the protein, as well as their relationship with the survival and prognosis of the disease.</p><p><strong>Methods: </strong>We retrieved reported mutations for <i>POLE</i> in EC from Catalogue of Somatic Mutations in Cancer database. We analyzed the most frequent mutations possible impact in the protein using HOPE server. We built a protein-protein network using Network Analyst, Cytoscape, and Network Analyzer plugin for topological analysis, enrichment analysis was performed using Gene Ontology: Biological processes. Clinical data was retrieved from cBioPortal database to compare overall survival between mutated <i>POLE</i> (<i>POLE</i>mut) and wild-type <i>POLE</i>. Relation of mutational status of <i>POLE</i> in EC and immune cell infiltration was analyzed using CIBERSORT algorithm in TIMER2.0 server.</p><p><strong>Results: </strong>Thirty mutations in POLE were retrieved, most reported mutations were p.P286R, p.V411L and p.A456P, these mutations were likely to be pathogenic. Network analysis of POLE showed interaction of this protein in biological processes such as DNA repair, the cell proliferation cycle, and mechanisms of resistance to platinum. Immune infiltration analysis showed that T cell CD8+, T cell memory activated CD4+, T cell follicular helper, T cell gamma delta and macrophage M1 were more infiltrated in EC <i>POLE</i>mut tumors.</p><p><strong>Conclusion: </strong>Mutations in POLE might affect DNA polymerase epsilon function. These mutations also affect interactions with other proteins like proteins involved in different DNA repairing mechanisms. <i>POLE</i> mutations may lead to platinum resistance, but they can also trigger an immune response that improves prognosis.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of cancer in pregnancy on obstetric and neonatal outcomes: an observational retrospective cohort study.","authors":"Xuan Huang, Chen Zhang, Jialei Zhu, Yueyan Li, Jing Tang","doi":"10.3802/jgo.2024.35.e74","DOIUrl":"10.3802/jgo.2024.35.e74","url":null,"abstract":"<p><strong>Objective: </strong>The study aimed to review the oncological characteristics and treatment of pregnancy-associated cancers and analyze the obstetric and neonatal outcomes to provide evidence-based recommendations for reproductive function preservation, oncological treatment, and obstetric management.</p><p><strong>Methods: </strong>We conducted an observational retrospective cohort study among pregnant patients with cancer in 7 Chinese tertiary A hospitals from 2003 to 2021. We conducted multiple logistic regression to determine the influence of various factors on preterm birth and small-for-gestational-age infants, log-binomial regression to analyze temporal changes, and χ² tests to explore the effects of cancer type/treatment.</p><p><strong>Results: </strong>Of 204 women, 17% terminated their pregnancies; 59% received pre-delivery treatment. Every 6 years, the rates of pregnancy termination (relative risk [RR]=0.48; 95% confidence interval [CI]=0.35-0.67) and iatrogenic preterm births (RR=0.73; 95% CI=0.54-0.98) reduced, and that of pre-delivery treatment increased, mainly due to increased rates of surgery (RR=1.87; 95% CI=1.31-2.67). Maternal systemic diseases were related to small-for-gestational-age infants (odds ratio [OR]=12.02; 95% CI=1.82-79.43). Chemotherapy with taxanes plus platinum-based agents was related to adverse obstetric outcomes (OR=1.87; 95% CI=1.42-2.46; p<0.05). Thyroid (OR=0.36; 95% CI=0.22-0.57) and ovarian cancer (OR=0.70; 95% CI=0.50-0.98) were associated with fewer cesarean sections. Thyroid cancer was associated with fetal growth restriction (OR=5.21; 95% CI=1.21-22.55).</p><p><strong>Conclusion: </strong>Rates of pregnancy termination in cancer declined. Taxane plus platinum-based chemotherapy was associated with adverse obstetric outcomes. Cancer type influenced outcomes.</p><p><strong>Trial registration: </strong>Chinese Clinical Trial Register Identifier: ChiCTR2100044292.</p>","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e74"},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}